Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fasudil hydrochloride + tirapibep
- Development stage
- Unknown
- Lead developer
- Asahi Kasei
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Fasudil hydrochloride + tirapibep is an experimental combination therapy being investigated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Fasudil hydrochloride is a small molecule inhibitor of Rho-associated protein kinase (ROCK), which plays a role in cell morphology, migration, and the tumor microenvironment. Tirapibep is a monoclonal antibody that acts as a checkpoint inhibitor by targeting the programmed cell death protein 1 (PD-1) receptor, thereby enhancing the immune system's ability to detect and destroy cancer cells. This combination is typically administered alongside androgen deprivation therapy (castration) to evaluate whether the synergistic effects of ROCK inhibition and PD-1 blockade can overcome resistance in advanced prostate cancer.
- Other names
- Fasudil hydrochloride combined with immunotherapyFasudil + TirapibepFasudil hydrochloride + Tirapibep
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)ROCK2 (Rho-associated coiled-coil containing protein kinase 2)ROCK1 (Rho-associated coiled-coil containing protein kinase 1)
Beyond the preview
Go deeper on fasudil hydrochloride + tirapibep.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fasudil hydrochloride + tirapibep.